Companies Century Therapeutics, Inc.
Century Therapeutics (IPSC): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Century Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,589,630FY2023
- $1,487,604FY2024
- $912,320FY2025
CEO total pay was $912,320 in fiscal 2025, down from $1,487,604 in fiscal 2024.
FY2025: salary $559,650 · bonus $0 · stock awards $71,120 · option awards $51,240
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chad Cowan | $559,532 | $0 | $398,329 | $8,327 | $201,007 | $0 | $0 | $1,167,015 |
| Chief Scientific Officer | ||||||||
| Adrienne Farid | 333,348 | 0 | 71,120 | 51,240 | 0 | 0 | 533,515 | 989,403 |
| Former Chief Development Officer | ||||||||
| Gregory Russotti | 559,650 | 0 | 71,120 | 51,240 | 226,658 | 0 | 3,652 | 912,320 |
| Chief Technology and Manufacturing Officer and former Interim President and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Chad Cowan | $1,167,015 | — | — | — |
| Adrienne Farid | 989,403 | 1,417,304 | 1,709,916 | ↓ −427,901 |
| Gregory Russotti | 912,320 | 1,487,604 | 2,589,630 | ↓ −575,284 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The compensation of our NEOs generally consists of base salary, annual cash incentive opportunities, long-term incentive compensation in the form of equity awards, and other benefits. Equity-based incentive awards are designed to align the interests of our stockholders with those of our NEOs.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Gregory Russotti | Option | 2,188 | 13.15 | — |
| Pfeiffenberger | RSU | 9,802 | — | 9,753 |
| Gregory Russotti | RSU | 13,500 | — | 13,433 |
| Chad Cowan | RSU | 19,500 | — | 19,402 |
| Chad Cowan | Option | 19,500 | 0.6 | — |
| Pfeiffenberger | Option | 31,056 | 1.61 | — |
| Gregory Russotti | Option | 51,044 | 4.64 | — |
| Chad Cowan | RSU | 55,782 | — | 55,503 |
| Pfeiffenberger | Option | 58,811 | 5.32 | — |
| Gregory Russotti | Option | 82,131 | 5.32 | — |
| Gregory Russotti | Option | 106,256 | 2.91 | — |
| Gregory Russotti | RSU | 120,000 | — | 119,400 |
| Gregory Russotti | Option | 120,000 | 0.6 | — |
| Pfeiffenberger | Option | 255,792 | 1.61 | — |
| Chad Cowan | Option | 316,096 | 1.65 | — |
| Pfeiffenberger | RSU | 521,500 | — | 518,892 |
| Pfeiffenberger | Option | 521,500 | 0.6 | — |
| Pfeiffenberger | RSU | 586,887 | — | 586,953 |
| Chad Cowan | RSU | 762,543 | — | 758,730 |
| Pfeiffenberger | RSU | 1,587,614 | — | 1,579,676 |
Director compensation
No director compensation table is on file for fiscal year 2025.
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Peer group, and who names Century Therapeutics as a peer
Companies that benchmark against IPSC
5 companies name IPSC as a compensation peer
- Adaptimmune Therapeutics PLCADAPFY2024
- Lineage Cell Therapeutics, Inc.LCTXFY2025
- Mersana Therapeutics, Inc.MRSNFY2024
- Passage BIO, Inc.PASGFY2025
- Shattuck Labs, Inc.STTKFY2025
Each company listed discloses IPSC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IPSC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Century Therapeutics, Inc. | 2025 | Gregory Russotti | $559,650 | $71,120 | $51,240 | $226,658 | $912,320 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (5 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Chad Cowan. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE”. As printed: 1,167,015. View filing ↗
- Section 01, Adrienne Farid. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE”. As printed: 989,403. View filing ↗
- Section 01, Gregory Russotti. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE” · page 21. As printed: 912,320. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Century Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Century Therapeutics, Inc.'s own proxy. As printed: 912,320. View filing ↗